BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35963605)

  • 1. NAFLD: genetics and its clinical implications.
    Sharma D; Mandal P
    Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):102003. PubMed ID: 35963605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
    Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
    J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics and epigenetics of NAFLD and NASH: Clinical impact.
    Eslam M; Valenti L; Romeo S
    J Hepatol; 2018 Feb; 68(2):268-279. PubMed ID: 29122391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
    Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
    Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on NAFLD genetics: From new variants to the clinic.
    Trépo E; Valenti L
    J Hepatol; 2020 Jun; 72(6):1196-1209. PubMed ID: 32145256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.
    Donati B; Dongiovanni P; Romeo S; Meroni M; McCain M; Miele L; Petta S; Maier S; Rosso C; De Luca L; Vanni E; Grimaudo S; Romagnoli R; Colli F; Ferri F; Mancina RM; Iruzubieta P; Craxi A; Fracanzani AL; Grieco A; Corradini SG; Aghemo A; Colombo M; Soardo G; Bugianesi E; Reeves H; Anstee QM; Fargion S; Valenti L
    Sci Rep; 2017 Jul; 7(1):4492. PubMed ID: 28674415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
    Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
    J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the genetics of nonalcoholic fatty liver disease.
    Ajmera V; Loomba R
    Curr Opin Gastroenterol; 2023 May; 39(3):150-155. PubMed ID: 37144531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
    Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
    Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and risk-stratification of NAFLD-associated HCC.
    Ioannou GN
    J Hepatol; 2021 Dec; 75(6):1476-1484. PubMed ID: 34453963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease.
    Chen Y; Du X; Kuppa A; Feitosa MF; Bielak LF; O'Connell JR; Musani SK; Guo X; Kahali B; Chen VL; Smith AV; Ryan KA; Eirksdottir G; Allison MA; Bowden DW; Budoff MJ; Carr JJ; Chen YI; Taylor KD; Oliveri A; Correa A; Crudup BF; Kardia SLR; Mosley TH; Norris JM; Terry JG; Rotter JI; Wagenknecht LE; Halligan BD; Young KA; Hokanson JE; Washko GR; Gudnason V; Province MA; Peyser PA; Palmer ND; Speliotes EK
    Nat Genet; 2023 Oct; 55(10):1640-1650. PubMed ID: 37709864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of host genetics on liver microbiome composition in patients with NAFLD.
    Pirola CJ; Salatino A; Quintanilla MF; Castaño GO; Garaycoechea M; Sookoian S
    EBioMedicine; 2022 Feb; 76():103858. PubMed ID: 35092912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis.
    Scott E; Anstee QM
    Clin Med (Lond); 2018 Apr; 18(Suppl 2):s54-s59. PubMed ID: 29700094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.
    Kawaguchi T; Shima T; Mizuno M; Mitsumoto Y; Umemura A; Kanbara Y; Tanaka S; Sumida Y; Yasui K; Takahashi M; Matsuo K; Itoh Y; Tokushige K; Hashimoto E; Kiyosawa K; Kawaguchi M; Itoh H; Uto H; Komorizono Y; Shirabe K; Takami S; Takamura T; Kawanaka M; Yamada R; Matsuda F; Okanoue T
    PLoS One; 2018; 13(1):e0185490. PubMed ID: 29385134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.